show case

February 2014
Pharmacy Today;Feb2014, Vol. 20 Issue 2, p19
Product Review
The article offers information on several drugs that were approved by the U.S. Food & Drug Administration including the H5N1 avian influenza vaccine from ID Biomedical Corp., the Raltegravir from Merck, and the Telmisartan immediate-release tablet angiotension II receptor blocker from Actavis.


Related Articles

  • Biotech Collaborations Between Pharmaceutical & Miscellaneous Companies: April 1 - May 16, 2013.  // BioWorld Insight;5/20/2013, Vol. 21 Issue 21, p18 

    A table is presented that lists biotechnology collaborations between several pharmaceutical and miscellaneous companies including Actavis Inc., DFH Pharma Inc. and Merck & Co. Inc. as of April 1-May 16, 2013.

  • PULSECX. McCaffrey, Kevin // Medical Marketing & Media;Jul2015, Vol. 50 Issue 7, p156 

    The article presents a profile of healthcare advertising agency PulseCX Inc. Topics include the company's May 2014 rebranding from Roska Healthcare Advertising, addition of new work from several pharmaceutical and medical device companies including Actavis PLC, Merck & Co. Inc. and Inspire...

  • OB/GYN.  // MPR - Pediatricians' Edition;Spring/Summer2014, Vol. 25 Issue 1, p102 

    The article offers information on several oral contraceptives including Pfizer Inc.'s Depo-Provera, Merck & Co. Inc.'s Implanon, and Actavis' Ella.

  • How key suppliers performed in 2014.  // Chain Drug Review;4/27/2015, Vol. 37 Issue 7, p21 

    The article reports on the earnings and performance of key suppliers and pharmaceutical companies in 2014 including Merck & Co., GlaxoSmithKline PLC, and Revlon Inc. Topics discussed include the increase of the combined earnings of pharmaceutical companies, the rebound from loss of...

  • Pharma: Clinic Roundup.  // BioWorld Today;11/15/2012, Vol. 23 Issue 223, p8 

    This article reports on the results of three studies which found that Merck & Co. Inc.'s integrase inhibitor Isentress (raltegravir) demonstrated consistent long-term viral suppression and safety profile in patients co-infected with HIV-1 and hepatitis C virus and/or hepatitis B virus.

  • FeverAll.  // Drug Store News;1/30/2012, Vol. 34 Issue 2, p58 

    The article offers brief information on the FeverAll acetaminophen suppositories from Actavis Inc.

  • Update.  // Medical Marketing & Media;Feb2014, Vol. 49 Issue 2, p11 

    The article offers U.S. marketing news briefs as of February 2014 on various topics including president of Novartis's oncology division, pipeline drug and restructuring generic drugmaker Actavis PLC.

  • Actavis.  // Chain Drug Review;9/28/2015, Vol. 37 Issue 15, p144 

    The article profiles Actavis PLC, a pharmaceutical company based in Dublin, Ireland which is focused on developing, manufacturing and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.

  • Allergan Adds To Aesthetics. Investor's Business Daily // Investors Business Daily;6/18/2015, pA01 

    9 The drugmaker formerly known as Actavis would buy biotech


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics